| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Ginkgolide B (Bilobalide B; BN-52051; BN52051) is a naturally occuring compound acting as a PAFR (platelet-activating factor receptor) antagonist with an IC50 of 3.6 μM.
| Targets |
PAFR ( IC50 = 3.6 μM )
|
||
|---|---|---|---|
| ln Vitro |
|
||
| ln Vivo |
|
||
| Animal Protocol |
|
||
| References |
[1]. Biochem Pharmacol . 1987 Sep 1;36(17):2749-52. [2]. Am J Physiol Renal Physiol . 2012 May 15;302(10):F1234-42. [3]. Eur Cell Mater . 2011 May 28:21:459-69. [4]. J Cereb Blood Flow Metab . 1990 Jan;10(1):133-5. [5]. Pharmacopsychiatry . 2003 Jun:36 Suppl 1:S8-14. [6]. Eur J Pharmacol . 1986 Aug 7;127(1-2):83-95. [7]. J Neurochem . 1988 Dec;51(6):1900-5. |
||
| Additional Infomation |
Ginkgolide B has been reported in Ginkgo and Ginkgo biloba with data available.
See also: Ginkgolide B (annotation moved to). |
| Molecular Formula |
C20H24O10
|
|
|---|---|---|
| Molecular Weight |
424.4
|
|
| Exact Mass |
424.136
|
|
| Elemental Analysis |
C, 56.60; H, 5.70; O, 37.70
|
|
| CAS # |
15291-77-7
|
|
| Related CAS # |
|
|
| PubChem CID |
65243
|
|
| Appearance |
White to off-white solid powder
|
|
| Density |
1.6±0.1 g/cm3
|
|
| Boiling Point |
762.4±60.0 °C at 760 mmHg
|
|
| Melting Point |
280°C (dec.)
|
|
| Flash Point |
274.3±26.4 °C
|
|
| Vapour Pressure |
0.0±5.8 mmHg at 25°C
|
|
| Index of Refraction |
1.651
|
|
| LogP |
0.52
|
|
| Hydrogen Bond Donor Count |
3
|
|
| Hydrogen Bond Acceptor Count |
10
|
|
| Rotatable Bond Count |
1
|
|
| Heavy Atom Count |
30
|
|
| Complexity |
925
|
|
| Defined Atom Stereocenter Count |
0
|
|
| SMILES |
O[C@H]1[C@]2([H])OC([C@@H](C)[C@]2(O)C23C(=O)O[C@@]4([H])C12C1([C@H](C(O[C@@]1([H])O3)=O)O)[C@@H](C4)C(C)(C)C)=O
|
|
| InChi Key |
SQOJOAFXDQDRGF-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C20H24O10/c1-6-12(23)28-11-9(21)18-8-5-7(16(2,3)4)17(18)10(22)13(24)29-15(17)30-20(18,14(25)27-8)19(6,11)26/h6-11,15,21-22,26H,5H2,1-4H3
|
|
| Chemical Name |
8-tert-butyl-6,12,17-trihydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.89 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.90 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.90 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 30% Propylene glycol , 5% Tween 80 , 65% D5W: 10mg/mL Solubility in Formulation 5: 5 mg/mL (11.78 mM) in 0.5% CMC-Na/saline water (add these co-solvents sequentially from left to right, and one by one), suspension solution; Need ultrasonic and warming and heat to 44°C. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3563 mL | 11.7813 mL | 23.5627 mL | |
| 5 mM | 0.4713 mL | 2.3563 mL | 4.7125 mL | |
| 10 mM | 0.2356 mL | 1.1781 mL | 2.3563 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT03772847 | Completed | Drug: ginkgolide | Intravenous Alteplase Thrombolysis Neurological Improving |
Second Affiliated Hospital, School of Medicine, Zhejiang University |
July 31, 2018 | Phase 4 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA